Amalia Gastaldelli
Overview
Explore the profile of Amalia Gastaldelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
9704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Gastaldelli A, Newsome P
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39970128
Several reasons led to the change in the nomenclature from non alcoholic fatty liver disease (NAFLD) to metabolic dysfunction associated steatotic liver disease (MASLD); the most important being limitations due...
3.
Patarrao R, Meneses M, Ghadieh H, Herrera L, Duarte S, Ribeiro R, et al.
Eur J Clin Invest
. 2024 Dec;
54 Suppl 2:e14344.
PMID: 39674875
Background: Type 2 diabetes (T2DM) and obesity are characterized by altered insulin metabolism and action. Reduced hepatic insulin clearance is increasingly recognized as a key contributor to hyperinsulinemia and insulin...
4.
Rayas M, Pezzica S, Honka H, Carli F, Peterson R, DeFronzo R, et al.
Obesity (Silver Spring)
. 2024 Dec;
33(1):104-115.
PMID: 39635951
Objective: The glycemic-independent actions of glucagon-like peptide-1 (GLP-1) in the prandial state in humans are unknown. We examined the contribution of GLP-1 to β-cell secretory response (primary endpoint) and glucose...
5.
Angelini G, Russo S, Carli F, Infelise P, Panunzi S, Bertuzzi A, et al.
FASEB J
. 2024 Nov;
38(22):e70202.
PMID: 39600104
Dodecanedioic acid (DC12) is a dicarboxylic acid present in protective polymers of fruit and leaves. We explored the effects of DC12 on metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DC12 supplementation...
6.
Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A
JHEP Rep
. 2024 Nov;
6(12):101185.
PMID: 39583092
Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is recognised as a metabolic disease characterised by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, alongside impaired oxidation and/or export of...
7.
Sabatini S, Sen P, Carli F, Pezzica S, Rosso C, Lembo E, et al.
Cell Rep Med
. 2024 Nov;
5(11):101820.
PMID: 39566466
Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with a high prevalence of type 2 diabetes (T2D). Individuals with MASLD exhibit insulin resistance (IR) and hyperglycemia, but...
8.
Manuguerra S, Carli F, Scoditti E, Santulli A, Gastaldelli A, Messina C
Metabolites
. 2024 Oct;
14(10).
PMID: 39452940
Over time, the scientific community has developed a growing interest in the effects of mixtures of different compounds, for which there is currently no established evidence or knowledge, in relation...
9.
10.
Lori G, Pastore M, Navari N, Piombanti B, Booijink R, Rovida E, et al.
JHEP Rep
. 2024 Oct;
6(10):101182.
PMID: 39430578
Background & Aims: Among the reprogrammed metabolic pathways described in cancer stem cells, aberrant lipid metabolism has recently drawn increasing attention. Our study explored the contribution of fatty acids (FA)...